Luo Min, Liu Rui-Na, He Zhen-Mei, Liang Qian-Fu, Huang Feng-Ling
Department of Pharmacology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530000, Guangxi Zhuang Autonomous Region, China.
Department of Radiotherapy, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530000, Guangxi Zhuang Autonomous Region, China.
World J Clin Oncol. 2025 May 24;16(5):105444. doi: 10.5306/wjco.v16.i5.105444.
Multiple primary carcinoma (MPC) refers to two or more types of primary malignant tumors occurring simultaneously or sequentially in the same patient. Breast cancer is one of the most common malignant tumors affecting women. On the other hand, diffuse large B-cell lymphoma (DLBCL) is the most frequent form of non-Hodgkin's lymphoma (NHL). In clinical practice, the simultaneous existence of metachronous primary breast cancer and lymphoma is rare. In this case, we highlight the significance of multidisciplinary management and advanced imaging techniques in the early identification and treatment of MPC cases.
In this study, we report a case of a 40-year-old female who was diagnosed with invasive ductal carcinoma of the breast (T3N1M0 stage IIIA LuminalB type) as the first primary cancer and DLBCL (stage IIIA) as the second primary cancer. The patient underwent the modified radical mastectomy for left breast cancer and received Rituximab, cyclophospha-mide, hydroxydaunorubicin, Oncovin (vincristine) and prednisolone regimen chemotherapy treatment for DLBCL. As of now, the patient is in stable condition. The successful diagnosis of the present patient highlights the need for multidisciplinary management and adoption of advanced imaging techniques to identify the second primary cancer, especially NHL.
Accurate diagnosis and management of metachronous MPC requires an interdisciplinary team and selection of an appropriate treatment plan.
多原发性癌（MPC）是指在同一患者体内同时或先后发生的两种或更多类型的原发性恶性肿瘤。乳腺癌是影响女性的最常见恶性肿瘤之一。另一方面，弥漫性大B细胞淋巴瘤（DLBCL）是非霍奇金淋巴瘤（NHL）最常见的形式。在临床实践中，异时性原发性乳腺癌和淋巴瘤同时存在的情况很少见。在此病例中，我们强调了多学科管理和先进成像技术在MPC病例早期识别和治疗中的重要性。
在本研究中，我们报告了一例40岁女性患者，她被诊断为浸润性导管癌（T3N1M0 IIIA期LuminalB型）作为第一原发性癌症，DLBCL（IIIA期）作为第二原发性癌症。该患者接受了左乳腺癌改良根治术，并接受了利妥昔单抗、环磷酰胺、羟基柔红霉素、长春新碱和泼尼松龙方案化疗治疗DLBCL。截至目前，患者病情稳定。本患者的成功诊断凸显了多学科管理以及采用先进成像技术来识别第二原发性癌症，尤其是NHL的必要性。
异时性MPC的准确诊断和管理需要一个跨学科团队并选择合适的治疗方案。
